Laboratorios Farmaceuticos ROVI Working Capital to Net Assets Ratio
Laboratorios Farmaceuticos ROVI working capital to net assets ratio. Laboratorios Farmaceuticos ROVI (ROVI) has a Working Capital to Net Assets ratio of 59.1% as of September 2025. Working capital of €373.77 Million (current assets of €559.19 Million minus current liabilities of €185.42 Million) is measured against net assets of €632.80 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Laboratorios Farmaceuticos ROVI (2004–2024)
Working capital to net assets ratio of Laboratorios Farmaceuticos ROVI from 2004 to 2024. This chart shows how Laboratorios Farmaceuticos ROVI's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2004 to 2024. As of September 2025, the ratio stands at 59.1%, reflecting working capital of €373.77 Million against net assets of €632.80 Million EUR. Explore Laboratorios Farmaceuticos ROVI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Laboratorios Farmaceuticos ROVI Working Capital to Net Assets Ratio by Year (2004–2024)
Laboratorios Farmaceuticos ROVI working capital to net assets ratio by year from 2004 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Laboratorios Farmaceuticos ROVI from 2004 to 2024, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Laboratorios Farmaceuticos ROVI total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 57.6% | €334.92 Million | €581.54 Million | €491.57 Million | €156.65 Million | ▲ +0.6 pp |
| 2023 | 56.9% | €309.49 Million | €543.49 Million | €509.33 Million | €199.84 Million | ▼ -6.2 pp |
| 2022 | 63.1% | €329.19 Million | €521.38 Million | €623.07 Million | €293.89 Million | ▼ -4.0 pp |
| 2021 | 67.1% | €315.97 Million | €470.98 Million | €506.36 Million | €190.39 Million | ▲ +2.4 pp |
| 2020 | 64.7% | €241.69 Million | €373.70 Million | €364.58 Million | €122.89 Million | ▼ -0.8 pp |
| 2019 | 65.5% | €211.18 Million | €322.39 Million | €317.88 Million | €106.71 Million | ▲ +7.6 pp |
| 2018 | 57.9% | €166.49 Million | €287.47 Million | €254.00 Million | €87.51 Million | ▲ +8.4 pp |
| 2017 | 49.5% | €94.94 Million | €191.69 Million | €168.17 Million | €73.22 Million | ▲ +0.1 pp |
| 2016 | 49.4% | €90.63 Million | €183.41 Million | €167.07 Million | €76.44 Million | ▼ -8.1 pp |
| 2015 | 57.6% | €94.86 Million | €164.78 Million | €154.08 Million | €59.23 Million | ▼ -5.5 pp |
| 2014 | 63.1% | €99.92 Million | €158.47 Million | €162.03 Million | €62.12 Million | ▲ +8.3 pp |
| 2013 | 54.8% | €79.14 Million | €144.46 Million | €137.48 Million | €58.34 Million | ▼ -5.2 pp |
| 2012 | 60.0% | €75.91 Million | €126.45 Million | €131.04 Million | €55.13 Million | ▼ -38.6 pp |
| 2011 | 98.6% | €112.42 Million | €113.98 Million | €169.18 Million | €56.76 Million | ▼ -7.3 pp |
| 2010 | 105.9% | €110.30 Million | €104.13 Million | €161.93 Million | €51.63 Million | ▲ +11.2 pp |
| 2009 | 94.7% | €67.71 Million | €71.50 Million | €131.46 Million | €63.75 Million | ▲ +29.5 pp |
| 2008 | 65.2% | €31.59 Million | €48.44 Million | €78.64 Million | €47.06 Million | ▼ -23.0 pp |
| 2007 | 88.2% | €45.79 Million | €51.92 Million | €80.31 Million | €34.52 Million | ▲ +23.0 pp |
| 2006 | 65.2% | €16.83 Million | €25.81 Million | €53.73 Million | €36.90 Million | ▲ +29.5 pp |
| 2005 | 35.7% | €1.72 Trillion | €4.80 Trillion | €5.07 Trillion | €3.35 Trillion | ▼ -60682.3 pp |
| 2004 | 60718.1% | €1.77 Billion | €2.92 Million | €5.40 Billion | €3.63 Billion | — |